Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eliquis followed by 3 drugs in a random order · 1 trial · 1 indication
Measured from blood samples
| Arm | Type | Description |
|---|---|---|
| Platelet function in healthy subjects administered sotagliflozin vs. antiplatelet agents | EXPERIMENTAL | Platelet responsiveness will be assessed in the blood from subjects administered sotagliflozin, aspirin, clopidogrel, or apixaban in randomized order given as a single drug administration. |
| Name | Type | Description |
|---|---|---|
| Sotagliflozin (SOTA) followed by 3 drugs in a random order | DRUG | 400 mg/day SOTA Each drug will be given daily for 2 weeks. |
| Aspirin followed by 3 drugs in a random order | DRUG | 81 mg/day Aspirin Each drug will be given daily for 2 weeks. |
| Clopidogrel followed by 3 drugs in a random order | DRUG | 75 mg/day clopidogrel Each drug will be given daily for 2 weeks. |
| Eliquis followed by 3 drugs in a random order | DRUG | 5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks. |
Inclusion Criteria: \- Exclusion Criteria: * Students under the direct supervision of Dr. Michael Holinstat * Subjects diagnosed with Type I diabetes or those with ketoacidosis * Subjects with a history of alcohol abuse, pancreatitis or pancreatic surgery, or subjects taking a ketogenic diet * Wo...
Eliquis is used for platelet function and reactivity tests. It is being studied in a clinical trial that compares its antiplatelet effects to FDA-approved antiplatelet drugs. The drug is in early Phase 1 development for this indication.
Eliquis is being developed by Lexicon Pharmaceuticals, Inc., a company traded on the NASDAQ under the ticker LXRX. The company is conducting a Phase 1 clinical trial to evaluate the drug's effects on platelet function and reactivity.
Eliquis is in early Phase 1 clinical development. The ongoing trial, NCT06933056, is currently recruiting participants in the United States. The drug is investigational and has not been approved for this use.
Eliquis is being studied in one clinical trial, NCT06933056, titled 'Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs.' This early Phase 1 trial is recruiting 20 healthy volunteers in the United States and is not randomized or double-blinded.
Eliquis is being studied under the name Sotagliflozin in the clinical trial NCT06933056. The trial compares the antiplatelet effects of Sotagliflozin to FDA-approved antiplatelet drugs, indicating that Eliquis and Sotagliflozin refer to the same drug in this context.